US Pharm. 2010;35(8):58.

Generic drug manufacturers will be granted voluntary licenses to the HIV/AIDS drug portfolio of ViiV Healthcare, in order to increase access to these medicines in countries with the highest HIV/AIDs burden. This offer extends to 69 low-income and less-developed nations, including all of sub-Saharan Africa; these countries are home to an estimated 80% of all people currently living with HIV/AIDS. The offer includes not only ViiV's current products, such as Combivir, Viracept, and Ziagen, but also drugs in their pipeline, including a novel protease inhibitor currently in development with the Japanese manufacturer Shionogi and Co. Ltd. ViiV is a joint venture of GlaxoSmithKline and Pfizer Inc.